Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Workman
Paul
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D004359:Drug Therapy, Combination; D000077156:Gefitinib; D015316:Genetic Therapy; D015894:Genome, Human; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D009857:Oncogenes / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; D000068878:Trastuzumab; D000077156:Gefitinib